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Background: In European countries, including Switzerland, as well as in many states worldwide, cannabis is the
most widely used psychoactive substance after alcohol and tobacco. Although approximately one in ten users
develop serious problems of dependency, only a minority attends outpatient addiction counseling centers. The
offer of a combined web-based self-help and chat counseling treatment could potentially also reach those users
who hesitate to approach such treatment centers and help them to reduce their cannabis use.
Methods/design: This paper presents the protocol for a three-armed randomized controlled trial that will test the
effectiveness of a web-based self-help intervention in combination with, or independent of, tailored chat counseling
compared to a waiting list in reducing or enabling the abstention from cannabis use in problematic users. The
primary outcome will be the weekly quantity of cannabis used. Secondary outcome measures will include the
number of days per week on which cannabis is used, the severity of cannabis use disorder, the severity of cannabis
dependence, cannabis withdrawal symptoms, cannabis craving, the use of alcohol, tobacco, and other
non-cannabis illicit drugs, changes in mental health symptoms, and treatment retention. The self-help intervention
will consist of 8 modules designed to reduce cannabis use based on the principles of motivational interviewing,
self-control practices, and methods of cognitive behavioral therapy. The two additional individual chat-counseling
sessions in the additional chat condition will be based on the same therapy approaches and tailored to participants’
self-help information data and personal problems. The predictive validity of participants’ baseline characteristics on
treatment retention and outcomes will be explored.
Discussion: To the best of our knowledge, this will be the first randomized controlled trial to test the effectiveness
of online self-help therapy in combination or without chat counseling in reducing or enabling the abstention from
cannabis use. It will also investigate predictors of outcome and retention for these interventions. This trial is
registered at Current Controlled Trials and is traceable as ISRCTN59948178.
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Cannabis is the most commonly used illicit drug in the
developed world; e.g., a rough European estimate suggests
that approximately 22% of Europeans within the ages of
15 and 64 have tried cannabis, and approximately 6.8% of
this population report using cannabis in the past month.
This represents 12 million Europeans, of whom 25%
report daily cannabis use [1]. Switzerland has the third
highest national prevalence of cannabis use in Europe; the
lifetime prevalence rate is 27.9% (men 32.8%, women
23.2%), and the 12-month prevalence rate is 5.1% (men
7.5%, women 2.8%) [2]. The age group with the highest
prevalence is between 15 and 24 years; this group has a
17.3% 12-month prevalence rate, and among these users
nearly one fifth use cannabis daily [2].
Despite these high numbers, only a minority of cannabis
users is at risk of cannabis dependence. Currently, the
estimates of the risks of cannabis dependence based on
general population surveys suggest that between 10 and
11 percent of all cannabis users develop cannabis depend-
ence [3,4]. However, the risks of cannabis dependence [5]
and cannabis use problems [6] are much higher among
cannabis users who consumed cannabis in early life. Daily
cannabis use is associated with poorer mental and physical
health, lower educational achievement, and decreased
cognitive functioning [7]. Moreover, there is clear evidence
from numerous studies that frequent cannabis use is
strongly associated with a broad range of primary mental
illnesses [8]. Thus, specific attention should be paid to
mental disorders in heavy cannabis users.
Treatment demand statistics from Swiss outpatient
addiction treatment centers demonstrate a linear increase
in new treatment entry cases in which cannabis is main
problem substance from 2003 (12%) to 2011 (46%) [9].
The main group of cannabis use disorder treatment
seekers consists of young males between the ages of 15
and 24 [9]. In Europe, an increase in the demand for
treatment in which cannabis is the main problem
substance has also observed, although smaller than that
in Switzerland [10]. However, it is obvious that the
majority of problematic cannabis users, of whom it is
estimated that one-half develop cannabis dependence [5]
and many demonstrate co-occurring mental health
problems, is still not in treatment.
There are several explanations for the low treatment
attendance rate of problematic cannabis users: 1) accessi-
bility—in many European countries and especially in
rural locations, addiction treatment services are scarce,
or treatment seekers are required to travel long distances
to more urban areas for access to treatment. Moreover,
the operating hours of addiction counseling centers are
typically during office hours, which make attendance
difficult for those cannabis users who have jobs and work
during these hours; 2) stigmatization and need for socialdistance—many problematic cannabis users do not want
to be stigmatized, desire personal distance from the
counselor [11], or simply want to quit on their own [12];
and 3) the scarcity of insight into the problem affects
motivation to change—many users see the risk of the
development of minor mental health problems, such as
mild depression symptoms, during ongoing problem
cannabis use but rarely see the physical risks such as the
development of COPD, lung cancer, and heart disease;
this phenomenon is more apparent in frequent users than
occasional users [13,14]. Those who are aware of such
physical risks from problematic cannabis use are also
more ready to quit [13]. Raising awareness of cannabis-
related physical health risks might also increase intentions
to reduce or quit cannabis use. In general, the principle of
concurrent cover (i.e., non-invasive, low-cost interventions
in which therapeutic intensity can be enhanced according
to need) appears to be an appropriate mean for problem-
atic cannabis users to lower their ever-increasing health
care costs [15], and this consideration is of interest to
Switzerland and other industrialized countries suffering
from exorbitant health costs.
Web-based self-help programs that reduce problematic
consumption are able to facilitate access to consumer
groups in the general population that do not want to be
stigmatized. Such programs have consistently been
shown to be effective in the reduction of problematic
alcohol use [16,17] and (although less efficiently and
consistently [17]) in tobacco smoking cessation [18,19].
Interestingly, the availability of web-based self-help with
individual chat sessions has been demonstrated to aid the
reduction of alcohol use and alcohol disorder-related
symptoms in problematic alcohol users [20].
Studies of web-based programs for the reduction of
the most frequently used illicit drugs, such as cannabis,
cocaine and amphetamines, are scarce [21,22]. Currently,
there are only two specific web-based programs for the
reduction of cannabis use that have been investigated in
randomized controlled trials, and these programs
employ different intervention approaches [23,24]. The
German “Quit the Shit” program [24] is based on princi-
ples of self-regulation and self-control and is a solution-
focused approach. This program is structured into
weekly personalized feedback sessions based on partici-
pants’ consumption diary entries, intake and termination
chats, and the total allowed program time is 50 days.
Attrition in the German study of Tossmann and colleagues
[24] was high and higher in the intervention (11.6%) con-
dition than in the waiting list control condition (24.7%).
Nevertheless, these authors found significant effects on
cannabis use reduction in their per-protocol and last
observation carried forward analyses. The Australian
program “Reduce Your Use: How to Break the Cannabis
Habit” [23] is a fully automated self-help intervention
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use disorders based on cognitive-behavioral therapy (CBT)
approaches [25,26], motivational interviewing (MI [27]),
and behavioral self-management (BSM [28]). This program
was tested for effectiveness in a randomized-controlled
trial and compared to a psycho-educative control condition
also consisting of 6 modules. Study retention was higher in
the intervention and the control condition after 6 weeks
(66% vs. 64%) and at a 3-month follow up (54% vs. 52%)
than in the aforementioned German study [24]. The fre-
quency of cannabis use and the quantity of cannabis con-
sumed were both more reduced in the intervention group
than in the control group at 6 weeks and at the 3-month
follow up.
The combination of a fully automated self-help interven-
tion based on therapy approaches of the study of Rooke
and colleagues [23] with additional individual chat sessions
for the reduction of cannabis use could potentially increase
the effectiveness of interventions for problematic cannabis
as has been demonstrated for the reduction of alcohol
use in problematic alcohol users [20]. More interactive
web-based interventions may be more effective in reducing
cannabis use in problematic cannabis users. However, the
results of the Australian study [23] need confirmation by
other studies. Specifically, the high rates of study retention
in the intervention and control groups may be due to
limited geographic access of many rural users to the addic-
tion treatment system in Australia, which did not appear
to be the case in the German study, which encountered
considerable retention problems [20]. Therefore, the
treatment approaches adopted for web-based self-help by
Rooke and colleagues [23] should also be validated in
countries with high densities of addiction counseling
services such as Switzerland.
The current study aims at to investigate and compare the
effectiveness of web-based self-help interventions in com-
bination with tailored chat counseling based on CBT, MI,
and BSM in reducing cannabis use in problematic cannabis
users. More specifically, this study aims to compare the
effectiveness of interventions that include chat-counseling
and web-based self-help, web-based self-help alone and a
waiting list control condition in the reduction of cannabis
use in problematic cannabis users in a three-arm random-
ized controlled trial.
Study interventions
The intervention in the first arm consists of the web-
based self-help intervention from study arm two in com-
bination with two individual chat-counseling sessions
based on MI and CBT approaches that are tailored to the
data the participants entered into the self-help interven-
tion and individual requests. The web-based self-help
intervention “Can Reduce” from study arm two is based
on classical CBT approaches for the treatment of cannabisdependence [26], MI approaches [27], and BSM [28].
Study arm three consists of a classical waiting list. Figure 1
presents a detailed overview of the aforementioned study
arms.
Study arm one and two involve weekly reminder e-mails
to login and fill out a consumption diary. The following
modules, organized into three main parts, are offered as a
web-based self-help intervention (study arms one and two):
 Part 1: Introduction
 Registration process
 Explanation of the cannabis consumption diary
and its fully automated progress charts and
statistics
 Examination of the pros and cons resulting from
a change in cannabis consumption patterns and
further principles of motivational interviewing to
address motivation
 Explanation of the “My Can Reduce” folder (this
folder allows individuals to review the acquired
summarized module documents, e.g., the list of
the top five strategies for dealing with cannabis
cravings)
 Explanation of the emergency button for
immediate responses to frequently asked
questions and access to emergency contacts Part 2: Key Modules (participants are encouraged to
complete these modules in the order presented
below)
 Module 1: Strategies for goal achievement
 Module 2: Identifying risk situations
 Module 3: Dealing with cannabis craving
 Module 4: Dealing with relapses Part 3: Further Modules (participants are
encouraged to complete at least two, in any order)
 Module 5: Tobacco smoking during the
reduction of cannabis use
 Module 6: Saying “no” to foster refusal skills
 Module 7: Dealing with burdens
 Module 8: Preserving achievementsFurthermore, a glossary that explains the terms, defini-
tions, and concepts used in the intervention, information
about the history of cannabis use, the short-, medium-
and long-term effects of cannabis, the physical risks of
cannabis (COPD, lung cancer, cardio-vascular, etc.),
co-occurring mental health problems (depression, psych-
osis, ADHD, etc.), and harm reduction techniques for the
use of cannabis with recommendations (these recom-
mendations favor oral intake and are based on the
recruitment
screening, 
informed consent
t0 measure
randomization
trial arm 1
self-help therapy 
plus chat
trial arm 3
waiting list control 
condition
t1 measure
3 months
trial arm 2
self-help therapy
only
t1 measure
t2 measure t2 measure t2 measure
8 weeks
6 weeks
Figure 1 Trial flowchart. This figure provides an overview of the participant flow for this trial.
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be provided in an appendix accessible after login, along
with frequently asked questions and their corresponding
answers.
The additional two chat counseling sessions in study
arm one will apply support regarding behavioral change
according to MI, discuss the modules of the web-based
self-help part based on MI and CBT, review the develop-
ment of the consumption diary and will be structured as
follows:
 Chat session 1: Starting point and objective
agreement
 Personalized feedback according to baseline
assessment of cannabis related physical and
mental health risks
 Review of successful strategies of change related
to topics other than cannabis
 Imagining daily routines after cannabis cessation;
exploration of aims to live without, and the
dissonances of, cannabis use; mobilization of
social support with the invitation for a relevant
third person to join chat session 2
 Agreeing on a cannabis use objective expressed in
tangible numbers (e.g., a maximum of two
standard joints per week, complete cannabis
abstinence etc.) Chat session 2: Experience exchange and
consolidation
 Experience exchange regarding the agreed-upon
objective since the starting point
 Review of the patterns of the consumption diary
goals and achievements Review and consolidation of web-based self-help
modules
 Experience and improvement of social support
 Revising objectives
 Saving strategies for long-term successThe web-based self-help intervention and the subse-
quent tailored chat counseling aim to reduce cannabis
use. However, those participants who seek cannabis
abstinence will also be encouraged to make step-by-step
reductions until full abstinence has been reached. The
maintenance of abstinence from one day to the next, as is
recommended by the content of tobacco prevention
websites [31], will not be advised for safety reasons (e.g.
to avoid possible severe withdrawal symptoms).
Participants randomized to the waiting list will have
the opportunity to participate in the web-based self-help
intervention 3 month after registration. Follow up
measures for those participants will be assessed online
or by telephone interviews for those participants who
cannot be reached online at the 3 month follow up.
Methods/design
Aims of the trial
This study aims to compare the effectiveness of a
web-based self-help intervention alone or combined with
chat counseling in the reduction of the cannabis use of
problematic cannabis users via a three-arm randomized
controlled trial. The primary outcome is the weekly
quantity of cannabis consumed (measured in the number
of standard joints per week) at the 3-month follow up.
The secondary outcome measures include the frequency
of cannabis use days (7 day point prevalence of cannabis
use days), changes in problematic cannabis use, severity
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cannabis craving, the use of other psychoactive sub-
stances, mental health symptoms, functional health states,
intervention satisfaction, and treatment retention. The
predictive validity of participant characteristics for treat-
ment retention and primary and secondary outcomes will
be explored.
Study population
The study population will be recruited through the Can
Reduce website, several websites from local outpatient
treatment centers, and from nightlife prevention web-
sites. In addition, advertisements will be placed in
internet-forums and (commuter) newspapers.
Hypotheses
We hypothesize that web-based interventions, which are
more interactive, will be more effective in reducing can-
nabis use among problematic cannabis users. We will
test the following detailed study hypotheses with respect
to the main outcome, i.e., reduction of the quantity of
cannabis used between the baseline and the 3-month
follow up:
1. Tailored chat-based counseling in combination with
web-based self-help for the reduction of cannabis
use (study arm 1) is more effective than the waiting
list control condition (study arm 3).
2. Web-based self-help for the reduction of cannabis
use (study arm 2) is more effective than the waiting
list control condition (study arm 3).
3. Chat-based counseling in addition to web-based
self-help for the reduction of cannabis use (study
arm 1) is by trend more effective than web-based
self-help alone (study arm 2).Table 1 Measurements and instruments
Assessments/instruments Baseline 1 week
Socio-demographics x
MHI-5 x
CLAMES1) x
Quantity of Cannabis use2) x x
Frequency of Cannabis use2) x x
CUDIT x
SDS x
CWS x
CCS-7 x
FDA x
Intervention Satisfaction
1) Additional retrospective cost-relevant information directly or indirectly related to
and cost-utility analyses.
2) 7-day point prevalences of the quantity (in common standard joints) and frequen
derived from the consumption diary assessed daily using data from the last 7 days.Moreover, we expect the participants of study arm 1
to improve more than those in study arm 2 with respect
to the secondary outcomes between the baseline and the
three-month follow up termination.
Measurement instruments
The primary outcome measures of cannabis consumption
will be recorded as the 7-day point prevalence of the
quantity of cannabis used, quantified in pre-defined stand-
ard cannabis joint sizes, as specified in the consumption
diary (see also Table 1). In the first step, participants will
choose between three different cannabis forms presented
in photographs (low potency cannabis plant, high potency
cannabis plant, or cannabis resin). In the second step, five
different standard joints for every category will be pre-
sented (1/10 g, 1/6 g, 1/4 g, 1/3 g, 1/2 g; pictures will
come from the global drug survey cannabis meter [32]);
these joints will either be pure cannabis or cannabis mixed
with tobacco. A standard tobacco cigarette, a ruler with
centimeter and millimeter scales, the fraction amount in
grams, and an open 10 cm paper prepared to roll a joint
and containing the cannabis plant/resin-tobacco mixture
or pure cannabis will be presented. Participants will
choose which picture most closely approximates the can-
nabis joints they most often smoke. Those who smoke
cannabis in different preparations (e.g., in a bong, a
vaporizer, etc.) will choose the photograph that most
closely approximates the amount of cannabis their usually
consume. The final chosen picture will be placed in the
individual consumption diary, and participants will be
asked to convert the quantities of the cannabis they
smoke into units relative to that picture if they consume
cannabis for once in forms other than their common
standard joint (rule of thumb that one high potency joint
is equal to two low potency cannabis joints of identical3 weeks 6 weeks 3-month follow up
x
x
x x x
x x x
x
x x
x
x
x x
x
cannabis use will be collected by the CLAMES to conduct cost-effectiveness
cy (the number of days on which cannabis is used) of cannabis use will be
Schaub et al. BMC Psychiatry 2013, 13:305 Page 6 of 10
http://www.biomedcentral.com/1471-244X/13/305content weight, one cannabis resin joint is equal to three
low potency joints of identical content weight, etc.; identi-
cal content weight pictures will be presented on a separ-
ate page). Participants will also have the opportunity to
indicate quantities below one common standard joint
down to one tenth of a joint (they will also be able to indi-
cate quarter-joint). Quantities smaller than one joint are
expected for those who share cannabis joints with others.
Moreover, the following secondary outcome instru-
ments will be applied: 1) cannabis consumption days per
week according to the consumption diary; 2) the Cannabis
Use Disorders Identification Test (CUDIT), which is a
10-item questionnaire [33] that was constructed by adapt-
ing the Alcohol Use Disorders Identification Test (AUDIT
[34]). To cover the length of the trial length, this instru-
ment will be adapted to focus on the last 3 months in its
planned assessments (baseline and 3-month follow up);
3) The Severity of Dependence Scale (SDS), which is a
5-item questionnaire that measures the severity of canna-
bis dependence. Each of the five items is scored on a
4-point scale (0–3). The total score is obtained through
the addition of the ratings on all 5 items. High scores indi-
cate high levels of dependency [35]; 4) The Cannabis
Withdrawal Scale (CWS) [36], which is a 26-item ques-
tionnaire containing statements that describe cannabis
withdrawal symptoms within the last 24 hours on 11-
point scales (0–10); 5) The Cannabis Craving Symptoms
questionnaire (CCS-7), which is a 7-item questionnaire
[37] derived from the Marijuana Craving Questionnaire
[38]. Each item is rated on a 7-point-scale (1–7); 6) the
“Fragebogen Substanzanamnese” (FDA), which is a ques-
tionnaire that ascertains the number of years of consump-
tion over the lifetime, the past month’s consumption, and
the manner of consumption for DSM-IV/ICD-10 sub-
stances of abuse. This measure was derived from the
Europe ASI [39]; 7) the short version of the Mental Health
Inventory (MHI-5) [40], which is a validated and user-
friendly self-assessment questionnaire that assesses recent
mental distress and self-reported diagnoses of depression;
8) the CLAMES, which is a standardized measure of func-
tional health states that provides a simple, genericTable 2 Inclusion and exclusion criteria and rationale
Inclusion Criteria
- Minimum age of 18 years
- At least once a week cannabis use over the 30 days prior to study entry
- Current serious psychiatric disease or history of psychosis, schizophrenia, bi
or significant current suicidal or homicidal thoughts
- Other pharmacological or psycho-social treatments for cannabis use disord
- Inability to read or write in German
- For women: pregnancy and breastfeedingmeasure of health for clinical and economic appraisal.
This instrument consists of a descriptive system to meas-
ure pain/discomfort, physical functioning, emotional state,
fatigue, memory and thinking, social relationships, anxiety,
speech, hearing, vision, and use of hands and fingers on
four or five levels that range from no problems to extreme
problems [41]. Overall intervention satisfaction will be
ascertained on a visual analogue scale from absolutely un-
satisfied to absolutely satisfied. Finally, retention will be
derived from the last cannabis use input entered into the
consumption diary in study arms one and two.
Estimation of the expected effect sizes and sample size
Based on results of the study of Rooke and colleagues
[23], we expect small to medium effect sizes for the
reduction of the quantity of cannabis used and the
frequency of cannabis use between study arm 2 (web-
based self-help without chat counseling) and study arm 3
(waiting list control) of at least 0.15 (Cohen’s f) between
t0 and t2. Assuming that the study arm 1 (web-based self-
help with chat counseling) will result in a larger Cohen’s f,
we rely on the aforementioned comparison (arm 2 vs. arm
3) for sample size estimation. A sample size of n = 89 in
each study group would have 80% power (F-test, α = 5%)
to detect this difference based calculations performed with
the G-Power software. Thus, we aim to recruit a total of
267 participants.
Consent procedure
The rationale of the study will be explained to the par-
ticipants. The participants will then be informed about
the following: (1) study inclusion and exclusion criteria
(see Table 2); (2) the three different arms and their 1:3
chance of being allocated into one of the arms; (3) the po-
tential risks of participation; (4) safety arrangements during
and after the study phase; (5) the inability of Can Reduce
(with or without chat counseling) to replace face-to-face
therapy for problematic cannabis use/abuse; and (6) the
circumstances under which they should contact their
general practitioner or a professional from a medical advis-
ory and emergency list that will be accessible at all timesReasoning
To ensure a minimal age of participation
To include occasional users to provide extended
study validity
polar type I disorder To avoid exacerbation of serious symptoms of
these severe psychiatric diseases
ers To avoid confounding treatment effects
To avoid confounding drug effects
To prevent subjects with these conditions from
entering the study
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informed that the study has been reviewed by the ethics
committee of the Canton of Zurich and given a declaration
of no objection (nihil obstat). Moreover, they will be
informed about their right to withdraw from the study at
any time without consequences except for the loss of
further compensation. Informed consent will be accepted
when participants click on a field on the informed consent
page and submit the consent by clicking a submission
button.
Baseline assessment
After providing informed consent, subjects who meet study
entry criteria will create a personal and secure login and
password (with automated real-time verification of the
passwords’ security level) and will receive an automated
e-mail notification with their access information. They will
then be directed to the baseline assessment of socio-
demographic characteristics and consumption patterns
(see Table 1). Participants that do not meet the inclusion
and/or meet one of the exclusion criteria (see Table 2) will
receive an explanation of why they will not be permitted to
participate in the study and will receive further recommen-
dations (e.g., not to reduce their consumption of cannabis
before visiting a physician and receiving any necessary
treatment, etc.). A decision tree for the possible inclusion
and exclusion criteria combinations will be constructed
and implemented. The completion of the baseline assess-
ment will allow participants to begin their study arm
according to an automated online allocation procedure.
Participants that do not fulfill the criteria can proceed
with the modules from the Can Reduce web-based self-
help intervention, but they will not participant in the
study (i.e., there will be no assessments or compensation).
Randomization and allocation
Once participants have completed their baseline assess-
ment, they will be randomized by a computer program
in a 1:1:1 ratio to 1 of 3 “parallel” groups, and this as-
signment will be automatically registered in the back-
ground database. As we offer full transparency on the
three groups, we expect a certain risk that some might
try to circumvent their assignment by registering an-
other account in hope to end up in a different group. In
case a participant surmounts the administrative hurdle,
he nevertheless will be assigned to the same group for a
certain amount of time, based on his IP-address.
Safety
During the 6-week therapy/intervention phase, partici-
pants will have the opportunity to contact an outpatient
clinic in a nearby city by telephone (lists with hours of
operation, web-links, postal addresses, and telephone
numbers will be provided in the appropriate language).Additionally, a medical advisory and emergency list that
is based on the web-based treatment guidelines of the
Federation of Swiss Psychologists [42] (in line with the
HONcode [43], a code of ethics for medical information
on the Internet) will be provided for cases of emergency.
This list will always be accessible to participants in all
study arms before, during, and after study participation
regardless of whether the participants withdraw from
the study. This list will include phone numbers for
emergency help lines and the contact information of the
study team and the webmaster.Experience, training and supervision of chat counselors
To ensure that chat counseling sessions in study arm
one are conducted in the same MI style and cover all
relevant points, the chat counselors will be trained MI
counselors with at least one year of experience in treat-
ing cannabis-abusing patients who will follow a check
list in each counseling session. Two senior psychiatrists
with extended face-to-face and web-based addiction
counseling/therapy experience will train and supervise
junior counselors. Specific addiction chat counseling
quality standards will be developed and implemented for
this study based on the EQUS treatment quality stan-
dards [44] and extended to Swiss national addiction
counseling quality standards.Trial flow
Figure 1 provides an overview of the trial flow. If a par-
ticipant successfully completes the baseline assessment
(t0), he or she will be introduced step-by-step into the
corresponding study arm, invited to participate in part
one (study arms 1 and 2), or informed that they will be
provided access to the web-based self-help within
approximately 12 weeks (waiting list condition). Partici-
pant in the intervention arms 1 and 2 will receive
automated e-mail notifications to login and enter their
cannabis consumption frequency and quantity into their
consumption diary every week. Access to all modules
will be unrestricted from day one. However, the partici-
pants will be encouraged to complete all key modules
(modules 1–4) in order, to complete at least two further
modules chosen from modules 5 to 8 and to repeat any
modules they feel they need or that they perceived as
helpful within the 6 weeks of duration of study arms 1
and 2.
Six weeks after the baseline assessment, participants
will again be invited by e-mail to login and complete the
final study assessment (t1). Participants will be invited to
complete the follow up assessment (t2) by an e-mail
message that will be sent 3 months after t0; this message
will inform the participants that completion of the entire
3-month follow up assessment will be compensated with
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Handling of study dropouts
Each week, participants in intervention arms one and two
will be sent an automated e-mail that will contain a re-
minder to login to their consumption diary, a reminder to
work on their modules and a direct link to the Can Reduce
login site. If participants do not log in, they will receive a
reminder e-mail every three days for the following two
weeks. If they do not continue their participation after
these reminders, they will be considered to have dropped
out of the study. Participants allocated to study arm 1 (chat
and self-help) will additionally be invited to the first chat
session at least three times over two weeks if they do not
respond. In each of these invitations they will be asked to
agree to attend two chat sessions on dates suggested by
their counselor. If the participants are unable to attend on
these dates, they will have the opportunity to suggestion
dates to the counselor. This procedure will be repeated
until a first chat date has been found. If participants do not
show up at the agreed chat date they will be sent new chat
dates until a first chat appointment occurs. If participants
do not reply after three invitations to schedule chat ap-
pointment, they will be considered to have dropped out of
the study. The second chat appointment will be scheduled
at the end of the first chat session. If participants do not
show up for the second session, they will be sent new chat
dates twice. Attendance of at least one chat appointment
will be required of the participants, otherwise they will be
considered to have dropped out. Participants in study arm
1 who discontinue their consumption dairies but proceed
with the chat session will not be considered as drop outs
and will be included in the study.
Data analysis
Data will be analyzed according to the intention-to-treat
principle (ITT). For the ITT analyses, we will apply the
multiple imputations procedure (MICE) of STATA, which
imputes missing data using all available baseline variables
(sociodemographic and health- and cannabis-related vari-
ables). Baseline measurements will be compared using
t- and Chi-squared tests. Differences between primary and
secondary outcome variables between baseline and the
follow up points will be tested using generalized estimat-
ing equation (GEE) models. GEE is a repeated-measures
regression model that takes into account the correlations
between the repeated measures from each person [45].
We will perform logistic GEE analyses for the binary out-
come variables and linear GEE analysis for continuous
outcome variables. Results from the imputed data set will
be cross-checked with the non-imputed data set.
We will conduct additional exploratory regression ana-
lyses to determine whether baseline variables predict theseverity of cannabis use disorder (CUDIT, SDS), cannabis
craving (CCS-7), cannabis withdrawal (CWS), reduced
psychiatric symptoms (MHI-5), and treatment retention.
For these analyses, we will use linear, multinomial, or
binary regression models depending on the scale of the
outcome measure.
Ethical review
This RCT will be executed in compliance with the
Helsinki Declaration and has been reviewed by the ethics
committee of the Canton of Zurich who have given their
declaration of no objection (KEK-StV-Nr. 15/13).
Discussion
To the best of our knowledge, this will be the first random-
ized controlled trial to test the effectiveness of online
self-help therapy alone or in combination with chat coun-
seling in reducing or enabling the abstention from canna-
bis use. This study will add to the ongoing discussion of
whether web-based interventions that are more interactive
are more effective in reducing substance use in problem-
atic users [20]. This study will also be the first to investigate
predictors of outcome and retention for online self-help
and for chat counseling that aim to facilitate the reduction
or cessation of cannabis use. If the efficacy of this form of
self-help is demonstrated in this RCT, this self-help inter-
vention will be integrated into the basic services for canna-
bis users of the national addiction internet portal of
Switzerland and will potentially be able to reach those can-
nabis users who have difficulties attending outpatient
addiction treatments that follow the principle of concur-
rent cover [15]. Specifically, people who rely on evening
sessions after work, those in need of social distance, and
those worrying about stigmatization [11] may profit from
this new addiction intervention. This intervention will fos-
ter problem insight regarding physical problems that can
accompany ongoing problematic cannabis use [13,14]
utilizing a non-directive MI self-help intervention and/or
chat counseling style.
Previous face-to-face therapy intervention research has
demonstrated that the goal of cannabis abstinence and
the desired goals regarding the reduction of cannabis use
change frequently in problematic cannabis users [46],
especially in those who choose abstinence as the agreed-
upon aim of therapy. Failure to reach the fixed consump-
tion aim might result in frustration, self-deception, or in
concealment of cannabis relapse from the therapist
during face-to-face therapy, which may result in mislead-
ing effects. In contrast to face-to-face therapy, Can
Reduce is anonymous and asks participants to re-login
weekly and to set daily consumption aims week-by-week
after the evaluation of past cannabis use. Moreover, the
chat counseling sessions are tailored to the aims reported
in the consumption diary and reported use. Thus, we
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nounced in the intervention arms.
Some participants may want to reduce their cannabis
use only marginally and might reach their aims in the
first weeks of the intervention, which might result in
discontinuation of participation in the online self-help
intervention. Therefore, we will recommend that partici-
pants reduce their cannabis by at least 20 to 30 percent in
the first week of the intervention and continue with this
strategy in subsequent weeks if they succeed. For partici-
pants who do not succeed, we will recommend that they
create more modest goals until their final aim is received.
Participants receiving chat counseling will additionally be
motivated by their counselors to avoid setting their goals
too low.
During the online implementation of the consumption
diary of the web-based self-help intervention, pilot partici-
pants stressed the importance of the definition of com-
mon standard joints as the most appropriate measure for
the consumption diary. On the one hand, the established
cannabis meter pictures from the global drug survey
website facilitated the pilot participants’ entry of their
cannabis use, and, on the other hand, they felt more
motivated by a tailored photograph than a written in-
struction. In our opinion, this is the most effective
method to collect appropriate quantity measures, espe-
cially from cannabis users who use cannabis several times
a day. However, as this is the first time this kind of quan-
tity measure will be used in a randomized controlled trial,
we will also rely on the number of days per week that
cannabis is used.
One specific problem involves the online implementa-
tion of informed consent. As in previous research [21],
we will rely on participants to click on a field on the
informed consent page and submit the consent with a
submission button. Thus, we must trust that the partici-
pants have read and understood the study information
and that they are at least 18 years old. However, as we
followed the recommendations of [47] and [48] regarding
the best implantation of online informed consent proce-
dures, we expect that the participants will read the study
information in full and provide informed consent.
Finally, another potential problem for this trial is the
expected high attrition rates at the end of online therapy
and at the follow up; this attrition will also likely be
higher in the waiting list control group. We will address
this issue in three ways: 1) all participants must invest
approximately 20 minutes for the baseline assessment,
which will select more motivated participants and pre-
vent the participation of un-motivated participants; 2)
participation in the 3-month follow up assessment will
be compensated by a 40 Euro incentive (an online vou-
cher or an online charitable donation); 3) all missing
values in the final data set will be imputed, a promisingapproach that, as shown by our Dutch colleagues, has
become increasingly important in e-health research [49].
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